Professor Mallika Imwong
My research works have focused on three aspects:
- to understand how drug resistance emerges and spreads in malaria parasites in Asia and Africa
- to detect and characterise the true epidemiology of malaria in low transmissions setting
- to investigate the biology of relapse of benign malaria.
I am currently involved in surveillance studies describing the molecular epidemiology of drug resistance in different parts of the region including Thai-Burmese border, Eastern Thailand, Cambodia, Vietnam, Laos PDA, and Afghanistan. A key objective is to determine the genetic and mechanistic basis for increased resistance of P. falciparum to artemisinin. The development of an inexpensive and effective genetic tool is essential for public health monitoring for artemisinin resistance. My ongoing projects will use genotyping markers or phenotypic properties for the fitness cost alleviating genetic variants validated loci and conduct follow-up molecular epidemiological surveys to assess their prevalence throughout the GMS in the current state of transmission. Therefore, this will also allow us to assess the potential of the GMS to develop drug resistance phenotypes and to evaluate the potential that such phenotypes emerge in other parts of the malaria world (such as Africa), as control programs progress towards elimination.
Transnational spread of multidrug resistant PfPailin
Study protocol: an open-label individually randomised controlled trial to assess the efficacy of artemether-lumefantrine prophylaxis for malaria among forest goers in Cambodia
Maude RJ. et al, (2021), BMJ Open, 11, e045900 - e045900
A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border.
Saito M. et al, (2021), BMC medicine, 19
Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
Hamaluba M. et al, (2021), The Lancet. Infectious diseases
Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial
McLean ARD. et al, (2021), The Lancet Infectious Diseases
Glucose-6-phosphate dehydrogenase mutations in malaria endemic area of Thailand by multiplexed high-resolution melting curve analysis.
Boonyuen U. et al, (2021), Malaria journal, 20